Abiopharma

🔍 SCHLEIFER LEONARD S (Director)

Company: REGENERON PHARMACEUTICALS, INC. (REGN)

Report Date: 2025-12-31

Detailed Transactions and Holdings:

• Acquired 28,570 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 243,093.00 | transaction_form_type: 4
• Sold 28,570 shares of Common Stock at $772.09 per share (Direct)
  Date: 2025-12-31 | Code: F | equity_swap_involved: 0 | shares_owned_after: 214,523.00 | transaction_form_type: 4
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: H | nature_of_ownership: By 2024 GRAT | shares_owned_after: 127,484.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: H | nature_of_ownership: By 2025 GRAT | shares_owned_after: 300,000.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: H | nature_of_ownership: By 401(k) Plan | shares_owned_after: 5,989.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 39,985.00
• Sold 28,570 shares of 2020 Performance Stock Units (Derivative)
  Date: 2025-12-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 595,077.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1

Footnotes:

• F1: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company.